Importance of medication adherence from the ONTARGET and TRANSCEND points of view

Fundamental and Clinical Pharmacology

Volumn 23, Issue 2, 2009, Pages 259-260

  Barrios, Vivencio ^a   Escobar, Carlos ^b   Echarri, Rocio ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

Adverse outcomes; Medication adherence; ONTARGET; TRANSCEND

Indexed keywords

TELMISARTAN;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIHYPERTENSIVE AGENTS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 62849094267     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00683.x     Document Type: Article

References (5)

1. Ho P.M., Magid D.J., Shetterly S.M. et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch. Intern. Med. (2008) 168 271 276.
2. Lee J.K., Grace K.A., Taylor A.J. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA (2006) 296 2563 2571.
3. Barrios V., Escobar C., Prieto L., Herranz I. Adverse events in clinical trials: is a new approach needed? Lancet (2008) 372 535 536.
4. ONTARGET Investigators, Yusuf S., Teo K.K. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. (2008) 358 1547 1559.
5. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet (2008) 9644 1174 1183.